Inhibrx Biosciences, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Inhibrx entered a second amendment with Oxford Finance LLC in July 2026 providing $325M in gross proceeds ($100M funded immediately; up to $225M available in future $50M+ tranches). Q2 2026 net loss was $36.7M ($2.34/share, 15.7M shares) vs. $28.7M ($1.85/share) in Q2 2025. Cash rose from $133.3M (June 30) to $219.5M (August 6) post-funding. R&D expenses increased to $23.9M (vs. $22.3M YoY) and G&A to $8.3M (vs. $6.4M YoY). Pipeline: ozekibart BLA filed for chondrosarcoma with April 2027 PDUFA date; INBRX-106 Phase 2 HNSCC data expected Q3 2026.
Why this rating
Financing is 186% of market cap, materially extending runway and reducing dilution risk. Offsets worsening burn rate and negative equity. Pipeline milestones on track but pre-commercial stage carries execution risk.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.